Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139181

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137681

Published: 2020

Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1866.

https://doi.org/10.1182/blood-2019-123483

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Chang Ki Min, MD PhD, Kihyun Kim, MD PhD, Seok Jin Kim, MD PhD, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han, MD PhD

Blood (2019) 134 (Supplement_1): 1847.

https://doi.org/10.1182/blood-2019-127643

Published: 2019

Journal Articles

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Blood (2019) 134 (Supplement_1): 3066.

https://doi.org/10.1182/blood-2019-126867

Published: 2019

Journal Articles

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Sang Eun Yoon, MD, Seok Jin Kim, MD PhD, Kihyun Kim, MD PhD

Blood (2019) 134 (Supplement_1): 5585.

https://doi.org/10.1182/blood-2019-127872

Published: 2019

Journal Articles

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Joon Young Hur, MD, Kang Kook Lee, MD, Jun Ho Jang, MD PhD, Kihyun Kim, MD PhD, Chul Won Jung, MD PhD, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2018-99-114858

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Joon Young Hur, MD, Kang Kook Lee, MD, Sang Eun Yoon, MD, Sehhoon Park, MD, Jangho Cho, MD, Youjin Kim, MD, Eunseok Jeon, MD PhD, Jinoh Choi, MD PhD, Gayeon Lee, MD PhD, Byungjun Kim, MD PhD, Ju Hong Min, MD PhD, Jung Sun Kim, MD PhD, Jung Eun Lee, MD PhD, Joon Young Choi, MD PhD, Seok Jin Kim, MD PhD, Jun Ho Jang, MD PhD, Won-Seog Kim, MD PhD, Chul Won Jung, MD PhD, Kihyun Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2018-99-114099

Published: 2018

Journal Articles

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Yong Park, MD, Dae Sik Kim, MD PhD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Eun Sang Yu, MD, Min Ji Jeon, MD, Hojoon Choi, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Kihyun Kim, MD PhD, Byung Soo Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2018-99-115625

Published: 2018

Journal Articles

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Seok Jin Kim, MD PhD, Yong Park, MD, Yeung-Chul Mun, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2018-99-115447

Published: 2018

Journal Articles

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Blood (2018) 132 (Supplement 1): 5637.

https://doi.org/10.1182/blood-2018-99-116844

Published: 2018

Journal Articles

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Nizar Bahlis, MD, Meletios A Dimopoulos, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, Maria Krevvata, PhD, Christopher Chiu, PhD, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD

Blood (2018) 132 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2018-99-112697

Published: 2018

Journal Articles

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Blood (2017) 130 (Supplement 1): 3114.

https://doi.org/10.1182/blood.V130.Suppl_1.3114.3114

Published: 2017

Journal Articles

Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia

Sang-A Kim, MD, Sung-Soo Yoon, MD PhD, Youngil Koh, MD, Dong-Yeop Shin, MDPhD, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD, Hyeon-Seok Eom, Je-Jung Lee, MD PhD, Jeong-Ok Lee, MD, Soo-Mee Bang, MDPhD

Blood (2017) 130 (Supplement 1): 1814.

https://doi.org/10.1182/blood.V130.Suppl_1.1814.1814

Published: 2017

Journal Articles

A Prognostic Scoring System for Patients with Multiple Myeloma Who Were Classified Stage II By Revised International Staging System

Sung-Hoon Jung, Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Seok Jin Kim, June-Won Cheong, Soo-Jeoong Kim, Jae-Sook Ahn, Seo-Yeon Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, Je-Jung Lee

Blood (2016) 128 (22): 3284.

https://doi.org/10.1182/blood.V128.22.3284.3284

Published: 2016

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma

Min Kyoung Kim, MD, Kihyun Kim, MD PhD, Dok Hyun Yoon, Cheolwon Suh, Jae Hoon Lee, MD, Sung-Hoon Jung, Je-Jung Lee, Hyo Jung Kim, Jin Seok Kim, Jeong-Ok Lee, Hyeon Seok Eom, MD PhD, Won Sik Lee, MD, Yeung-Chul Mun, Young Rok Do, Hye Jin Kang

Blood (2016) 128 (22): 5683.

https://doi.org/10.1182/blood.V128.22.5683.5683

Published: 2016

NARROW

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Review of 20 Years Outcome of Multiple Myeloma Novel Agent Era at Samsung Medical Center, a Korean Cancer Center

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia

A Prognostic Scoring System for Patients with Multiple Myeloma Who Were Classified Stage II By Revised International Staging System

Bortezomib-Melphalan-Prednisone (VMP) Versus MP As Initial Treatment for Patients Older Than 75 Years with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only